Eligibility for lipid-lowering drug therapy in primary prevention: How do the Adult Treatment Panel II and adult treatment panel III guidelines compare?

Circulation

Volumn 105, Issue 2, 2002, Pages 136-139

  Gotto Jr , Antonio M ^a   Kuller, Lewis H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Atherosclerosis; Cholesterol; Drugs; Editorials; Prevention

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY RISK; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0037080907     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/circ.105.2.136     Document Type: Editorial

References (24)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
2. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study
6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
8. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: Projected impact on size, sex, and age distribution of the treatment-eligible population
9. The effect of race and sex on physicians' recommendations for cardiac catheterization
10. Coronary artery disease prevention: What's different for women?
11. Diabetes mellitus and coronary heart disease in the elderly
12. Diabetes mellitus: Subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality
13. Populations: Women and cardiovascular disease
14. Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: The Cardiovascular Health Study
15. Age and gender distributions of coronary artery calcium detected by electron beam tomography in 35 246 adults
16. Mismatch of coronary risk and treatment intensity under the National Cholesterol Education Program guidelines
17. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: The Cardiovascular Health Study
18. Assessment of subclinical atherosclerosis and cardiovascular risk
19. Coronary and aortic calcification among women 8 years after menopause and their premenopausal risk factors
20. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Quebec Cardiovascular Study
21. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease
22. The metabolic syndrome, LDL particle size, and atherosclerosis: The Atherosclerosis and Insulin Resistance (AIR) study
23. Cholesterol fighters lower heart attack risk, study finds